Winn Awards Help Physicians Solve Healthcare Disparities

March 26, 2024 01:10 PM GMT | By 3BL
 Winn Awards Help Physicians Solve Healthcare Disparities
Image source: Kalkine Media

Dr. Thomas Odeny grew up in rural Kenya during the height of the HIV epidemic in sub-Saharan Africa. After graduating from medical school at the University of Nairobi, he decided to begin his career in HIV care as a way to give back to his community.

“My home district had the highest prevalence of HIV in Kenya at the time,” says Thomas. “I had one brother living with HIV and one who died from it, so I felt this is where I was needed.”

Thomas initially saw a lot of late-stage HIV and witnessed the cancers that were prevalent in the early stages of the HIV epidemic, such as Kaposi sarcoma. He ultimately decided to pursue a career in internal medicine and medical oncology, and he notes that while rates of HIV-related cancers have declined in many patient populations over the years, Black communities worldwide have seen unchanged or increased incidence. In fact, Black people with cancers such as Kaposi sarcoma have significantly higher mortality than other groups.

“In addition, people living with HIV and cancer are excluded from clinical trials for reasons not clinically sound,” he says. “Thus, I am working to reverse this trend, and my research is helping address other barriers to care.”

Today, Thomas treats patients at the Siteman Cancer Center at Barnes-Jewish Hospital and at Washington University School of Medicine, St. Louis. He is one of ten Gilead-sponsored scholars who received the Winn Career Development Award (CDA) last fall through the Robert A. Winn Diversity in Clinical Trials Award Program (known as the Winn Awards). His clinical research grant focuses on expanding clinical trials and treatment options for cancer in underrepresented people living with HIV in underserved regions.

Dr. Joannie Ivory, Assistant Professor of Medicine at University of North Carolina, Chapel Hill (UNC) and UNC Lineberger Comprehensive Cancer Center, is part of the same Winn CDA cohort as Thomas. Her grandmother’s personal battle with colon cancer helped shaped her medical career path.

“What better way for me to show up for my grandmother and support her in her journey with colon cancer than to become an oncologist,” says Joannie.

As a Black physician, Joannie is all too familiar with the health inequities Black women with breast cancer face, such as having twice the incidence rate of triple-negative breast cancer (TNBC) and a 40% greater risk of mortality than white women.

“Black women are not asked to join research studies to the degree they should be,” she says. Joannie believes there are unconscious biases where providers assume certain people don’t want to participate in trials or target patient populations that are easiest to enroll.

Her research team recently closed their trial to non-Black participants when the preset target accrual was reached, leaving the trial open to only Black participants. When given the opportunity, enrollment among her target demographic of Black women increased, supporting her hypothesis that the barrier is not solely a trust issue.

Winn Awards and Gilead’s Commitment to Health Equity
The Winn Awards aim to address the longstanding lack of diversity in clinical trials by training, developing and mentoring early-stage investigator physicians from diverse backgrounds, as well as physicians who have a demonstrated commitment to increasing diversity in clinical research. The program was started by the Bristol Myers Squibb Foundation in 2020 and gained Gilead’s support when Chief Medical Officer Merdad Parsey learned of it.

“The program aligns perfectly to Gilead’s deep commitment to health equity, inclusion and representation in clinical trials,” Merdad says. “With this third cohort of physicians, we are looking forward to continuing to increase awareness, education and investment in diverse clinical trials.”

Winn CDA recipients receive a $120,000 annual grant for two years, in addition to mentorship from a seasoned clinical investigator at the sponsoring institutions. They go through training in trial design and community engagement methods and actively participate in their mentor’s clinical trial.

Thomas feels the program paired him with the ideal mentor. “In the 80s, my mentor, Dr. Lee Ratner of Washington University School of Medicine, published the first sequences of the HIV-1 virus before becoming an oncologist,” he says. “He also started the only clinic in the Midwest for cancer in people living with HIV, and now I’m helping run the clinic with him.”

For Joannie, receiving this award means she can advance one of her goals of bringing resources to underserved areas by achieving not only equality, but equity. “Equality means we’re dispersing all of the resources to everyone evenly and equity is shifting resources to areas that need it the most,” she says.

Joannie and Thomas both say they’re grateful to have the extra support to help improve health equity and benefit more people living with cancer and HIV through their research.

“When we include those who are normally not represented, we help everyone,” Thomas says.

Originally published by Gilead Sciences


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next